Martin Rohrbach

Martin Rohrbach

Partner, Life Sciences

The decline of the traditional pharmaceutical business model

As the sector stands at a crossroads, the traditional pharmaceutical business model may become obsolete. Although it may be too late to halt its decline, it’s certainly not too late to rethink how pharmaceuticals can adapt and thrive in the face of shifting payer attitudes and patient empowerment.
8 1

Value-based pricing in pharmaceuticals: Hype or Hope?

In the face of stagnant healthcare budgets and ever-growing demand for care, pharmaceutical companies are under severe pressure to demonstrate the value of their products. Value-based pricing has exciting potential to help improve patient outcomes – and at an affordable cost.
10